Futura Medical is a pharmaceutical group that develops innovative products targeting pain relief and sexual health. Its product portfolio offers genuine innovation in markets of significant commercial size, including erectile dysfunction, condoms and pain relief. One of the Company's key assets is its proprietary drug delivery technology, DermaSys® which focuses on targeted delivery through the skin.

Futura has a small and flexible core team, complemented by specialist consultants and other out-sourced services. This structure controls costs whilst giving the Company access to expert advisers. Futura's commercialisation strategy is based on out-licensing to major pharmaceutical and healthcare groups in return for milestone and royalty payments.

Futura's business model is founded on:

  • Advanced transdermal technology - leveraging Futura's novel intellectual property to offer innovative delivery of proven compounds through the skin to improve their performance or to address new indications
  • Controlled development risk - using only approved generic compounds to control the risk profile
  • Strong intellectual property - developing products where Futura can secure strong patent protection
  • Commercialisation - out-licensing to leading healthcare companies which offer the optimum potential financial returns

Futura shares trade on the AIM market of the London Stock Exchange.